Literature DB >> 7248960

Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism.

S Y Mishkin, R Pollack, M A Yalovsky, H P Morris, S Mishkin.   

Abstract

The local growth rate of Morris Hepatoma 44 (generation time, 6 months) was inhibited by 66 to 87%, and host survival was prolonged by 36 to 78% after the induction of hypothyroidism within 2 weeks of tumor implantation by propylthiouracil (0.1% in Purina chow), 131I(1 mCi/100 g body weight i.p.), or surgical thyroidectomy. In additional experiments, we studied the effects of inducing hypothyroidism (131I) at different stages in the natural history of Morris Hepatoma 44 on local and metastatic growth as well as on host survival. Induction of hypothyroidism within 2 weeks of tumor implantation (Group I) reduced local tumor growth as well as the number and size of pulmonary metastases, and prolonged survival by 70 to 80%. Induction of hypothyroidism at 6 weeks postimplantation when tumors were palpable (Group II) inhibited local growth by 39%, reduced the number and size of pulmonary metastases by approximately 80%, and prolonged host survival by 35%. Initiation of 131I treatment at 11 weeks when microscopic pulmonary emboli were present in most animals (Group III) reduced local growth by 19% and the number and size of pulmonary metastases by 72 and 50%, respectively. In this case, survival was prolonged by 17%. We conclude from these results that the local and metastatic growth of Morris hepatoma 44 as well as host survival are thyroid hormone-dependent processes. The mechanisms responsible for these observations remain to be explained.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248960

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Authors:  Manuela Schmidinger; Romano Danesi
Journal:  Oncologist       Date:  2017-11-16

Review 2.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

3.  Methimazole slows hepatocyte streaming in rats.

Authors:  R Oren; G Zajicek; Y Maaravi; G Kenet; F Karmely; A Hubert; P Raanani; N Arber
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

Authors:  Aleck Hercbergs; Rebecca E Johnson; Osnat Ashur-Fabian; David H Garfield; Paul J Davis
Journal:  Oncologist       Date:  2014-11-19

Review 5.  Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.

Authors:  Qianyu Tang; Min Zeng; Linxi Chen; Nian Fu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

6.  Effect of thyroid hormone-nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice.

Authors:  Javier Carmona-Cortés; Isabel Rodríguez-Gómez; Rosemary Wangensteen; Inmaculada Banegas; Ángel M García-Lora; Andrés Quesada; Antonio Osuna; Félix Vargas
Journal:  Tumour Biol       Date:  2014-02-20

Review 7.  Primary hepatocellular carcinoma. Present state of the disease and prospects for the future.

Authors:  C J Oon; M A Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.

Authors:  Bénédicte F Jordan; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2012-05-21       Impact factor: 5.810

Review 9.  Involvement of Thyroid Hormones in Brain Development and Cancer.

Authors:  Gabriella Schiera; Carlo Maria Di Liegro; Italia Di Liegro
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 10.  The role of thyroid hormone signaling in the prevention of digestive system cancers.

Authors:  Adam R Brown; Rosalia C M Simmen; Frank A Simmen
Journal:  Int J Mol Sci       Date:  2013-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.